You have 9 free searches left this month | for more free features.

Bortezomib

Showing 26 - 50 of 1,116

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Multiple Myeloma, Myeloma Multiple, Myeloma Trial in Poitiers (Drug and medical device)

Not yet recruiting
  • Multiple Myeloma
  • +2 more
  • Drug and medical device
  • Poitiers, France
    CHU Poitiers
Jun 1, 2023

Multiple Myeloma, High-Risk Cancer Trial in Montreal (Bortezomib following nonmyeloablative allogeneic transplant)

Active, not recruiting
  • Multiple Myeloma
  • High-Risk Cancer
  • Bortezomib following nonmyeloablative allogeneic transplant
  • Montreal, Quebec, Canada
    Hôpital Maisonneuve-Rosemont
Aug 22, 2022

Waldenström's Macroglobulinemia Trial in Ulm (Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab,

Active, not recruiting
  • Waldenström's Macroglobulinemia
  • Dexamethasone, Rituximab, Cyclophosphamide
  • Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
  • Ulm, Germany
    University Hospital Ulm
May 26, 2022

Multiple Myeloma, Auto Stem Cell Transplant Trial in Hackensack (Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Auto Stem Cell Transplant
  • Bortezomib
  • Hackensack, New Jersey
    John Theurer Cancer Center @ Hackensack University Medical Cente
Dec 23, 2022

Multiple Myeloma Trial (pomalidomide, Bortezomib, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jun 20, 2022

Multiple Myeloma, Myeloma Trial in Poitiers (Isatuximab, Lenalidomide, Bortezomib)

Active, not recruiting
  • Multiple Myeloma
  • Myeloma
  • Poitiers, France
    CHU Poitiers
Sep 5, 2022

Amyloidosis; Systemic Trial in Beijing (Daratumumab, Bortezomib, Dexamethasone)

Active, not recruiting
  • Amyloidosis; Systemic
  • Beijing, China
    Peking Union Medical College Hospital
May 9, 2022

Multiple Myeloma Trial in Oslo, Stavanger, Trondheim (Isatuximab, bortezomib, lenalidomide, dexamethason)

Recruiting
  • Multiple Myeloma
  • Isatuximab, bortezomib, lenalidomide, dexamethason
  • Roskilde, Denmark
  • +3 more
Sep 20, 2022

Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)

Withdrawn
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Jan 26, 2023

Antibody-mediated Rejection Trial in Tehran (Bortezomib)

Recruiting
  • Antibody-mediated Rejection
  • Bortezomib
  • Tehran, Iran, Islamic Republic of
    SBMU
Jan 27, 2022

Plasma Cell Myeloma Trial in Rochester (Bortezomib, Daratumumab, Dexamethasone)

Recruiting
  • Plasma Cell Myeloma
  • Bortezomib
  • +3 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Relapsed or Refractory Multiple Myeloma Trial in Beijing (Mitoxantrone Hydrochloride Liposome injection, Bortezomib for

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Mitoxantrone Hydrochloride Liposome injection
  • +2 more
  • Beijing, Beijing, China
    Beijing Chaoyang Hospital, Capital Medical University
Jan 16, 2022

Solitary Plasmacytoma Trial in Beijing (radiotherapy, Bortezomib Injection, Lenalidomide)

Recruiting
  • Solitary Plasmacytoma
  • radiotherapy
  • +3 more
  • Beijing, China
    Peking Union Medical College Hospital
Apr 22, 2022

Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Nov 28, 2023

Multiple Myeloma Based on Multi-omics

Enrolling by invitation
  • Multiple Myeloma
  • Bortezomib
  • Bortezomib
  • Beijing, China
    Beijng Chao Yang Hospital
Apr 21, 2022

Multiple Myeloma Trial in Hackensack (Fludarabine monophosphate, melphalan, Bortezomib)

Completed
  • Multiple Myeloma
  • Fludarabine monophosphate, melphalan, Bortezomib
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Apr 29, 2022

GVHD Trial in New York (Bortezomib, Cyclophosphamide)

Active, not recruiting
  • GVHD
  • New York, New York
    New York University School of Medicine
Apr 15, 2022

Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)

Withdrawn
  • Multiple Myeloma
  • Refractory Multiple Myeloma
  • nonmyeloablative allogeneic hematopoietic stem cell transplantation
  • +7 more
  • (no location specified)
Jan 4, 2023

Primary Systemic Amyloidosis, Light Chain Deposition Disease Trial in United States (drug, genetic, other, procedure)

Active, not recruiting
  • Primary Systemic Amyloidosis
  • Light Chain Deposition Disease
  • bortezomib
  • +6 more
  • Denver, Colorado
  • +6 more
Aug 24, 2022

Graft-versus-host Disease Trial in New York (Cyclophosphamide, Abatacept, Bortezomib)

Recruiting
  • Graft-versus-host Disease
  • New York, New York
    NYU Langone Health
Mar 24, 2022

Hematological Malignancy Trial in Detroit (Bortezomib)

Recruiting
  • Hematological Malignancy
  • Bortezomib
  • Detroit, Michigan
    Henry Ford hospital
Dec 23, 2021

Multiple Myeloma Trial in Germany, Greece (Daratumumab, Bortezomib, Dexamethasone)

Completed
  • Multiple Myeloma
  • Berlin, Germany
  • +9 more
May 27, 2022

Lymphoma, Mantle Cell, Mantle Cell Lymphoma Trial run by the NCI (Rituximab (R), EPOCH, Bortezomib (B))

Active, not recruiting
  • Lymphoma, Mantle Cell
  • Mantle Cell Lymphoma
  • Rituximab (R)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 21, 2021

Multiple Myeloma Trial in Chicago, Milwaukee (Bortezomib, Isatuximab, Cyclophosphamide)

Recruiting
  • Multiple Myeloma
  • Bortezomib
  • +3 more
  • Chicago, Illinois
  • +1 more
Mar 14, 2022

Relapsed or Refractory Multiple Myeloma Trial in China (SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone))

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • SVd (Selinexor+Bortezomib+dexamethasone)
  • Vd (Bortezomib+dexamethasone)
  • Hefei, Anhui, China
  • +33 more
Aug 14, 2022